Bart Filius, Director, on July 17, 2026, executed a purchase for 150,000 shares in Proqr Therapeutics N.v. (PRQR) for $257,925. Following the Form 4 filing with the SEC, Filius has control over a total of 300,000 ordinary shares of the company, with 300,000 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1612940/000110465926085234/xslF345X05/tm2620903-1_4seq1.xml